Evidence map›Paper›PMID 31645846›Full record

ArticleEXCLI journal2019

Delta-Aminolevulinate dehydratase and glutathione peroxidase activity in Alzheimer's disease: a case-control study.

Quelen Iane Garlet, Maria Vaitsa Losh Haskel, Romaiana Picada Pereira, Weber Cláudio Francisco Nunes da Silva, João Batista Teixeira da Rocha, Cláudia Sirlene Oliveira, Juliana Sartori Bonini

Open access · greenAbstract read
In one paragraph

Article in EXCLI journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Platelets mirror changes in the frontal lobe antioxidant system in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Quelen Iane GarletDepartamento de Farmacologia, Instituto de Ciências Biológicas, Universidade Federal de Rio Grande, Rio Grande/RS, Brazil.
Maria Vaitsa Losh HaskelDepartamento de Fisiologia Humana, Universidade Federal do Rio Grande do Sul, Porto Alegre/RS90040-060, Brazil.
Romaiana Picada PereiraDepartamento de Química, Universidade Estadual de Ponta Grossa, Ponta Grossa/PR, Brazil.
Weber Cláudio Francisco Nunes da SilvaUniversidade Estadual do Centro-Oeste, Campus CEDETEG, Departamento de Farmácia, Guarapuava/PR, Brazil.
João Batista Teixeira da RochaDepartamento de Bioquímica e Biologia Molecular, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria/RS, Brazil.
Cláudia Sirlene OliveiraDepartamento de Bioquímica e Biologia Molecular, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria/RS, Brazil.
Juliana Sartori BoniniUniversidade Estadual do Centro-Oeste, Campus CEDETEG, Departamento de Farmácia, Guarapuava/PR, Brazil.
Universidade Estadual do Centro-Oeste · BRUniversidade Federal de Santa Maria · BRUniversidade Estadual de Ponta Grossa · BRUniversidade Federal do Rio Grande · BRUniversidade Federal do Rio Grande do Sul · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative pathology that affects elderly people all over the world. Several studies have demonstrated that oxidative stress is an aggravating factor for AD development and progression. Therefore, this study aimed to evaluate the activity of two oxidative stress markers, glutathione peroxidase (GPx) and δ-aminolevulinate dehydratase (δ-ALA-D), as well as correlate them with blood metal levels and AD progression. For this purpose, 88 elderly individuals were divided in two groups: AD group (34 patients diagnosed with AD) and control group (34 subjects paired by age with the AD group). The Mini-Mental State Examination and the Clinical Dementia Rating (CDR) were used as tools to classify the AD progression. GPx and δ-ALA-D activities were measured in all subjects through blood tests. Both enzymes' activities were decreased in AD patients when compared to the age-matched control group, regardless of the CDR. Moreover, GPx activity was positively correlated with selenium levels in the blood; and the δ-ALA-D activity was negatively correlated with blood copper levels. Taken together, our results indicated that, for the first time, blood δ-ALA-D activity was significantly inhibited in AD patients. While literature reports conflicting data regarding GPx activity in AD patients, the δ-ALA-D activity seems to be a more consistent tool to be applied as an earlier AD marker.

Indexed as

AD markerAlzheimer's diseaseCDRdelta-ALA-DGpxMMSE

Identifiers

PMID31645846
PMCPMC6806262
OpenAlexW2990999432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.